Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
489 Leser
Artikel bewerten:
(2)

Devo Technology: Devo Announces $100 Million Funding Round Led by Eurazeo to Fuel Global Expansion and Acquisitions

Finanznachrichten News

Cloud-Native Logging and Security Analytics Leader Boosts Valuation to $2 Billion

CAMBRIDGE, Mass., June 02, 2022, the cloud-native logging and security analytics company, today announced $100 million in Series F funding at a valuation of $2 billion. Eurazeo-a leading global investment firm with over $30 billion in assets under management-led the round, and all other existing investors-Insight Partners, Georgian, TCV, General Atlantic, Bessemer Venture Partners, Kibo Ventures-also participated. Additionally, ISAI Cap Venture provided a strategic investment in the round. The round brings the total capital raised to more than $500 million. The new funding will fuel growth in new regions and verticals, accelerate Devo's delivery of the "autonomous SOC" and fund potential new M&A expansion.

The funding round comes on the heels of Devo's acquisition of Kognos, the AI-powered threat hunting pioneer, which marked a key step in delivering what Devo calls the autonomous SOC- complete visibility, automation, analytics, and open access to community expertise and content.

"Security teams are facing more threats than ever-regardless of industry or geography-and that challenge is compounded by the difficulty of hiring and retaining talent, a lack of visibility into the full attack surface, and the speed and scale necessary to keep up with not just growing threats, but the growth of their organizations," said Marc van Zadelhoff, CEO of Devo. "This round of funding allows us to deliver on the autonomous SOC through continued innovation of our technology, expand to more regions to serve more customers, and consider more M&A opportunities. We're thrilled to have instilled such confidence in our investors that they continue to support our innovation and the value we deliver to customers."

Devo will continue to drive expansion in new verticals and geographies, particularly the public sector and the Asia-Pacificit was designated as Federal Risk and Authorization Management Program's (FedRAMP) "In-Process" and expects to reach full authorization in the fall of 2022. Devo has also seen substantial growth in the APAC region, including adding energy provider Powerco as a customer and deploying an in-region AWS environment for customers and partners.

"Devo has proven to be a disruptive force in the security analytics market and we believe in its vision to fundamentally change the way organizations secure their data," said Guillaume d'Audiffret, Managing Director at Eurazeo, who joins the Devo Board. "It is setting a pace for innovation that will enable its customers to meet the ever-growing challenges facing security teams and we look forward to continuing our work together with Devo and fellow investors to further develop its market leadership."

The round comes as Devo closes out an impressive fiscal year of aggressive growth, including:

  • Nearly 100% annual revenue growth
  • Nearly 100% customer growth for the year, including Sonos, AT&T, and Unisys
  • Achieving FedRAMP "In-Process" status (https://www.devo.com/newsarticle/devo-reaches-fedramp-in-process-status/), and adding public sector customers including Ivy Tech Community College and Oklahoma University
  • Surpassing 500 employees across North America, Europe, and APAC, including 91 new hires so far in 2022
  • Acquisition of Kognos (https://www.devo.com/newsarticle/devo-acquires-ai-powered-security-automation-innovator-to-deliver-the-autonomous-soc/), an AI-powered security automation innovator
  • Launch of Devo Exchange (https://www.devo.com/newsarticle/devo-launches-application-marketplace-to-accelerate-time-to-value-for-customers-and-partners/), a community-based application marketplace for Devo customers and partners

The funding announcement coincides with the launch of a newly established team of security researchers and data scientiststo form Devo SciSec, led by Chief Technology Officer, Gunter Ollmann.

About Devo
Devo is the only cloud-native logging and security analytics platform that releases the full potential of your data to empower bold, confident action. With unrivaled scale to collect all of your data without compromise, speed to give you immediate access and answers, and clarity to focus on the signals that matter most, Devo is your ally in protecting your organization today and tomorrow. Headquartered in Cambridge, Massachusetts, with operations in North America, Europe and Asia-Pacific, Devo is backed by Insight Partners, Georgian, TCV, General Atlantic, Bessemer Venture Partners, Kibo Ventures and Eurazeo. Learn more at www.devo.com.

Devo PR Contact:
Shannon Todesca
shannon.todesca@devo.com
+1 (781) 797-0898


© 2022 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.